Bullish & Foolish
Full APRE fundamentals All 466 on the Survival Watch

APREAprea Therapeutics, Inc.

Is Aprea Therapeutics struggling financially?

Yes, by its own account. Aprea Therapeutics told the SEC on 13 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Cries for help

  • Reverse stock split

    We believe that effecting the Reverse Split will help us avoid delisting from Nasdaq and any resulting consequences.

    Form DEF 14A, filed 30 Apr 2026. Read it on SEC.gov

  • Trial setback

    In December 2020, we announced that our pivotal Phase 3 trial failed to meet its predefined primary endpoint of complete remission (CR) rate.

    Form 10-Q, filed 13 May 2026. Read it on SEC.gov

Signs of a way out

Nothing in the filings we have read names a way out.

Sector
Biotech/Pharma
Market cap
$8.1M
Source filing
10-Q 13 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 19months

    If the burn speeds up

    Empty by Jan 2028

  • 27months

    If it eases off

    Empty by Sep 2028

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$41.2M

÷

Cash burned over the last 12 months

$21.7M

What Aprea Therapeutics told the SEC

…our current and projected business operations and our financial condition and results of operations. We have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern. Risks related to the discovery, development and commercialization of our product candidates We are substantially dependent on the success of APR-1051 and ATRN-119. Our clinical…

Aprea Therapeutics, Inc., Form 10-Q, filed 13 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 466.2% share-count increase The company issued stock. Each share now owns 82.3% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt